Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 5/2004

01-10-2004 | Review Article

Pimozide in Dermatologic Practice

A Comprehensive Review

Authors: Dr Cynthia R. Lorenzo, John Koo

Published in: American Journal of Clinical Dermatology | Issue 5/2004

Login to get access

Abstract

Pimozide is an antipsychotic drug of the diphenylbutylpiperidine class. In the US, it is FDA-approved only as a backup treatment for Gilles de la Tourette syndrome, although it has been used in other countries for many years as a treatment for schizophrenia. In the past 20 years, pimozide has been found to be especially efficacious in the treatment of monosymptomatic hypochondriacal psychoses and is used by psychiatrists and dermatologists for this off-label purpose. In particular, pimozide is considered the treatment of choice for delusions of parasitosis. In addition, pimozide has been found to be efficacious in the treatment of body dysmorphic disorder, metastatic melanoma, trichotillomania, and trigeminal and postherpetic neuralgia. This review aims to familiarize physicians, especially dermatologists, on the uses of pimozide in dermatologic practice. A review of the literature was performed and the relevant information synthesized to give a complete overview of the drug and its therapeutic uses in dermatology.
Literature
1.
Janssen PAJ, Brugmans J, Dony J, et al. An international double-blind clinical evaluation of pimozide. J Clin Pharmacol 1972; 12: 26–34
2.
Janssen PAJ, Niemegeers CJE, Schellekens KHL, et al. Pimozide: a chemically novel, highly potent and orally acting neuroleptic drug. Arzneimittel Forschung 1968; 18: 261–87PubMed
3.
Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001; 19: 179–97PubMed
4.
Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991; 52: 221–33PubMed
5.
Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5–14PubMed
6.
Gould R, Murphy K, Reynolds I, et al. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A 1983; 80: 5122–5PubMedCrossRef
7.
Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33: 149–60PubMedCrossRef
8.
Creese I, Feinberg AP, Snyder SH. Butyrophenone influences on the opiate receptor. Eur J Pharmacol 1976; 36: 231–5PubMedCrossRef
9.
Cohen ML, Carpenter R, Schenck K, et al. Effect of nitrendipine, diltiazem, trifluoperazine and pimozide on serotonin2 (5-HT2) receptor activation in the rat uterus and jugular vein. J Pharmacol Exper Therap 1986; 238: 860–7
10.
Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996; 124: 35–9PubMedCrossRef
11.
Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27–38PubMed
12.
Driscoll MS, Rothe MJ, Grant-Kels JM, et al. Delusional parasitosis: a dermatologic, psychiatric and pharmacologic approach. J Am Acad Dermatol 1993; 29: 1023–33PubMedCrossRef
13.
Pinder R, Brogden P, Sawyer P, et al. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976; 12: 1–40PubMedCrossRef
14.
The Scottish Schizophrenic Research Group. The Scottish first episode schizophrenia study: II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 1987; 150: 334–8CrossRef
15.
Koo J, Lee CS. Delusions of parasitosis; a dermatologist’s guide to diagnosis and treatment. Am J Clin Dermatol 2001; 2: 285–90PubMedCrossRef
16.
Lindskov R, Baadsgaard O. Delusions of infestation treated with pimozide. Acta Derm Venereol 1985; 65: 267–70PubMed
17.
Chouinard G, Lehmann HE, Ban TA. Pimozide in the treatment of chronic schizophrenic patients. Curr Ther Res 1970; 12: 598–603PubMed
18.
Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987; 144: 673–5PubMed
19.
Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics 1987; 79: 1032–9PubMed
20.
21.
Shopsin B, Selzer G. High-dose pimozide in acutely ill, newly admitted schizophrenic inpatients. Curr Ther Res 1977; 21: 755–67
22.
Shatzberg AF, Cole JO, Degattista C. Manual of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 1997: 154–155
23.
Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82PubMedCrossRef
24.
Task force on DSM-IV. Diagnostic and statistical manual of mental disorders: text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000
25.
Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr 2002; 7: 453–63PubMed
26.
Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull 1996; 32: 597–605PubMed
27.
Hamann K, Avnstrop C. Delusions of infestation treated by pimozide: a double blind crossover clinical study. Acta Derm Venereol 1982; 62: 55–8PubMed
28.
Ungvari G, Vladar K. Pimozide treatment for delusion of infestation. Act Nerv Super (Praha) 1986; 28: 103–7
29.
Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry 1995; 40: 616–22PubMed
30.
Reilly T, Batchelor D. The presentation and treatment of delusional parasitosis: a dermatological perspective. Int Clin Psychopharmacol 1986; 1: 340–53PubMedCrossRef
31.
Johnson GC, Anton RF. Pimozide in delusions of parasitosis [letter]. J Clin Psychiatry 1983; 44: 233PubMed
32.
Munro A. Monosymptomatic hypochondriacal psychosis manifesting as delusions of parasitosis. Arch Dermatol 1978; 114: 940–3PubMedCrossRef
33.
Riding J, Munro A. Pimozide in the treatment of monosymptomatic hypochondriacal psychosis. Acta Psychiatr Scand 1975; 52: 23–30PubMedCrossRef
34.
Zanol K, Slaughter J, Hall R. An approach to the treatment of psychogenic parasitosis. Int J Dermatol 1998; 37: 56–63PubMedCrossRef
35.
Damiani JT, Flowers FP, Pierce DK. Pimozide in delusions of parasitosis. J Am Acad Dermatol 1990; 22: 312–3PubMedCrossRef
36.
37.
Sheppard N, O’Loughlin S, Malone J. Psychogenic skin disease: a review of 35 cases. Br J Psychiatry 1986; 149: 636–43PubMedCrossRef
38.
Zomer SF, De Wit RF, Van Bonswijk JE, et al. Delusions of parasitosis: a psychiatric disorder to be treated by dermatologists?. An analysis of 33 patients. Br J Dermatol 1998; 138: 1030–2PubMedCrossRef
39.
Koo J, Gambla C. Delusions of parasitosis and other forms of monosymptomatic hypochondriacal psychosis. Dermatol Clin 1996; 14: 429–38PubMedCrossRef
40.
Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 2000; 43: 683–6PubMedCrossRef
41.
De Leon OA, Furmaga KM, Canterbury AL, et al. Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997; 27: 403–9PubMedCrossRef
42.
Moretti M. Psychosomatic dermatologic symptoms (Hungarian). Orv Hetil 2000; 141: 169–72PubMed
43.
Freyne A. Delusions of infestation: a case report of response to risperidone. Ir Med J 1999; 92: 435PubMed
44.
Gallucci G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics 1995; 36: 578–80PubMedCrossRef
45.
Cetin M, Agargun MY, Yigit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 1999; 60: 554PubMedCrossRef
46.
Safer DL, Roth WT. Risperidone in the treatment of delusional parasitosis: a case report. J Clin Psychopharmacol 1997; 17: 131–2PubMedCrossRef
47.
Weintraub E. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12: 247–9PubMed
48.
Fawcett RG. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Clin Psychiatry 2002; 63: 169CrossRef
49.
Yorston G. Treatment of delusional parasitosis with sertindole. Int J Geriatr Psychiatry 1997; 12: 1127–8PubMedCrossRef
50.
Hopkinson G. The psychiatric syndrome of infestation. Psychiatr Clin 1973; 6: 330–45
51.
King BH. Hypothesis: involvement of the serotonergic system in the clinical expression of monosymptomatic hypochondriasis. Pharmacopsychiatry 1990; 23: 85–9PubMedCrossRef
52.
Botschev C, Müller N. Opiate receptor antagonist for delusions of parasitosis. Biol Psychiatry 1991; 30: 530–1PubMedCrossRef
53.
Fernandez A. Pimozide in delusional dysmorphosis. Can J Psychiatry 1988; 33: 425–6PubMed
54.
Dorian BJ. Monosymptomatic hypochondriacal psychosis [letter]. Can J Psychiatry 1979; 24: 377
55.
Pollock BG. Successful treatment of pathological jealousy with pimozide. Can J Psychiatry 1982; 27: 86–7PubMed
56.
Munro A. Excellent response of pathological jealousy with pimozide. CMAJ 1984; 131: 852–3
57.
58.
Lane RD. Successful fluoxetine treatment of pathologic jealousy. J Clin Psychiatry 1990; 51: 345–6PubMed
59.
Stein DJ, Hollander E, Josephson SC. Serotonin reuptake blockers for the treatment of obsessional jealousy. J Clin Psychiatry 1994; 55: 30–3PubMed
60.
Munro A, O’Brian JV, Ross D. Two cases of “pure” or “primary” erotomania successfully treated with pimozide. Can J Psychiatry 1985; 30: 619–22PubMed
61.
Costanza ME, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 1977; 40: 1010–5PubMedCrossRef
62.
Rigel DS, Murray T, Bolden S, et al. Malignant melanoma: prevention, early detection and treatment in the 21st Century. CA Cancer J Clin 2000; 50: 215–30PubMedCrossRef
63.
64.
Wick MM, Byers L, Frei E. L-Dopa: selective toxicity for melanoma cells in vitro. Science 1977; 197: 468–9PubMedCrossRef
65.
Wick MM, Byers L, Frei E. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 1978; 71: 163–4PubMed
66.
Wick MM, Byers L, Frei E. Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep 1982; 66: 1657–9PubMed
67.
Taub RN, Baker MA. Treatment of metastatic malignant melanoma with pimozide. Lancet 1979; I: 605CrossRef
68.
Neifeld JP, Tormey DC, Baker MA, et al. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients. Cancer Treat Rep 1983; 67: 155–7PubMed
69.
Krummel TM, Neifeld JP, Taub RN. Effects of dopamine agonists and antagonists on murine melanoma. Cancer 1982; 49: 1178–84PubMedCrossRef
70.
Stein DJ, Hollander E. Low dose augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53: 123–6PubMed
71.
Delzell JEJ, Grelle AR. Trigeminal neuralgia: new treatment options for a well-known cause of facial pain. Arch Fam Med 1999; 8: 264–8PubMedCrossRef
72.
Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46: 960–3PubMedCrossRef
73.
74.
Duke EE. Clinical experience with pimozide: emphasis on its use in postherpetic neuralgia. J Am Acad Dermatol 1983; 8: 845–50PubMedCrossRef
Metadata
Title
Pimozide in Dermatologic Practice
A Comprehensive Review
Authors
Dr Cynthia R. Lorenzo
John Koo
Publication date
01-10-2004
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 5/2004
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200405050-00007

Other articles of this Issue 5/2004

American Journal of Clinical Dermatology 5/2004 Go to the issue

Leading Article

The Potential Role of Allergen-Specific Sublingual Immunotherapy in Atopic Dermatitis

Therapy in Practice

Management of Bullous Pemphigoid

Therapy in Practice

Management of Cutaneous Warts

Guest Commentary

Poly-L-Lactic Acid

Adis Drug Profile

Poly-L-Lactic Acid

Guest Commentary

Poly-L-Lactic Acid